中国Proposed ChangesUpdates and Changes
2019年11月21日

AI, Big Data, and Blockchain - CNIPA seeks public comment on draft patent examination guidelines

Exciting new changes continue to happen with the Chinese Patent Office (CNIPA). On November 12, 2019, the CNIPA published a new set of amendments to Part II Chapter 9 of the Patent Examination Guidelines (“Draft”) and requested public comment by December 11, 2019.

In summary, the new guidelines clarify how emerging technologies involving artificial intelligence, Internet +, big data and blockchain should be examined. More specifically, the Draft provides examination guidelines for inventions comprising certain abstract features such as algorithms, business methods and rules.  

Examination Criteria

Accordingly to the newly amended guidelines in the Draft, when determining patent eligibility, novelty or inventive step (Articles 25, 2, and 22 respectively), examiners should consider the technical features and the abstract features as a whole, not separately in a vacuum.

The Draft explicitly states that if a claim comprises technical features in addition to abstract features, the claim as a whole should not be considered “rules and methods for mental activities” ( Article 25, Item 2, first paragraph), but instead should be considered patent-eligible subject matter.

The Draft further emphasizes if a claim recites technical means that use laws of nature to solve a technical problem, and thereby obtains technical effects in accordance with the laws of nature, the solution should be considered a “technical solution” (Article 2, second paragraph), not “rules and methods for mental activities”.

With respect to novelty and inventiveness, the examiner must consider the technical contributions of the abstract features and how they functionally support and interact with the technical features.

Examination Examples

The Draft provides ten examination examples, including several positive and negative examples of inventions incorporating abstract ideas. We will examine these examples in more detail in subsequent blog posts.

In practice, examiners tend to hastily challenge patent-eligibility when they encounter claims that involve algorithms or business methods/rules. Up until now, it has been extremely difficult for applicants to persuade examiners to change their minds. The Draft’s examples and statements clarify the requirements for both examiners and applicants, which should streamline patent examination in the future.

Drafting Requirements

The Draft also refines the requirements for drafting the description and claims for such applications. The description should describe how the technical features and the abstract features function together as a whole to bring forth beneficial effects. The Draft emphasizes that the claims should recite both (1) the technical features and (2) the abstract features which functionally support and interact with the technical features.

Eagle Thoughts

The above draft amendments provide a break in the long-felt problem in Chinese patent prosecution, in which examiners dissected a claim into “technical” vs “non-technical” or “abstract” parts, and ignored the abstract part of the claim altogether when evaluating patentability. As a result, inventions that were highly innovative could be rejected since the remaining “technical” parts per se lacked inventiveness. The current proposal resolves the significant difficulties that Applicants often faced when prosecuting software patent applications.  

This standard is also very much in line with the global trend in this area, such as the USPTO’s recent “relaxations” of its own examination guidelines, giving patent eligibility to inventions that integrate abstract ideas into practical applications.

We think these amendments provide innovators in areas such as AI, big data, and blockchain a much improved chance of obtaining patent protection for their inventions. This is in line with the current drive for technological advancement in China, with computer science being one of the most important areas of industrial development. We welcome the continual harmonization of global patent legal concepts, which we hope will streamline and facilitate the patent process not just for Chinese companies, but for all innovators around the world.

About the Authors

Sally Yu is a Chinese Patent Attorney at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

Jennifer Che, J.D. is Vice President and Principal at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

[email protected]

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

其他文章

China Releases Details on Patent Term Extension, Deferred Examination and More in the Latest Draft Implementation Rules of the New Chinese Patent Law

2020年12月11日
The China National Intellectual Property Administration (CNIPA) is moving forward at breakneck speeds aiming to get all the necessary pieces in place for the June 1, 2021 date when the new 4th Amendment of the Patent Law will come into effect. Most recently, this means a flurry of drafts coming out from CNIPA, including, but […]

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 1: Delayed Examination

2024年1月25日
December 2023 appears to have been an exceptionally busy and fruitful month in the China patent space. Following the State Council’s approval of the long-awaited Patent Law Implementation Regulations (“Regulations”, similar to the CFR in the US) in November, the CNIPA finally made public the full text of the Regulations just before the arrival of […]

Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical

2023年12月12日
Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]

China Forges Ahead with Draft Measures for New Patent Linkage System

2020年10月19日
Update! The finalized Implementation Measures are now out. You can read the details here: Breaking: China Released New Implementation Measures for the New Patent Linkage System Last month September 11, 2020, China’s National Medical Products Administration (NMPA) and the China National Intellectual Property Administration (CNIPA) jointly issued a draft set of measures for public opinion […]

我们的过去活动

Top crossarrow-right